Gene · 9682
Papers1,858
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 1,858
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Histone demethylase KDM4A promotes endometrial cancer progression through an ERRγ-associated cell-cycle regulatory axis. | Int J Biol Sci | 2026 | 42807380 | PubTator, text mining | PubMed |
| KDM4A-driven epigenetic reprogramming as a central nexus linking metabolic adaptation, immune remodeling, and therapy resistance in cancer. | Crit Rev Oncol Hematol | 2026 | 42624180 | PubTator, text mining | PubMed |
| Design and synthesis of quinazoline derivatives as novel JMJD3/HDAC dual-target inhibitors. | RSC Med Chem | 2026 | 42445800 | PubTator, text mining | PubMed |
| Integrated structure-based and fragment-guided design of isonicotinic acid derivatives as potential KDM4A inhibitors: an in silico study. | J Comput Aided Mol Des | 2026 | 42371179 | PubTator, text mining | PubMed |
| H2AX C-Terminal Dipeptide Truncation: A Master Switch of the DNA Damage Response. | bioRxiv | 2026 | 42182341 | PubTator, text mining | PubMed |
| Identification of 2-Substituted-3-Hydroxy-2,3-Dihydroquinazolin-4(1H) Ones as Cell-Active Inhibitors of KDM4A Lysine Demethylase. | ChemMedChem | 2026 | 42157714 | PubTator, text mining | PubMed |
| DNASE1L3 functions as a significant metastatic suppressor by attenuating MYH9/β-catenin/c-Jun/LncRNA-KDM4A-induced E-cadherin ubiquitination degradation in nasopharyngeal carcinoma. | Cell Mol Biol Lett | 2026 | 42092754 | PubTator, text mining | PubMed |
| Androgen receptor as a therapeutic target in endometrial cancer: a narrative review. | Int J Gynecol Cancer | 2026 | 42070324 | PubTator, text mining | PubMed |
| The combinations of histone lysine demethylase inhibitors with panobinostat exert enhanced effects against head and neck cancer cells. | Exp Cell Res | 2026 | 42019757 | PubTator, text mining | PubMed |
| Targeting Ferroptosis With Natural Products for the Treatment of Skeletal System Disease: An Updated Review. | J Cell Mol Med | 2026 | 41928432 | PubTator, text mining | PubMed |
| Protein arginine methyltransferases in cancer: mechanisms, functions, and therapeutic opportunities. | J Biomed Sci | 2026 | 41928257 | PubTator, text mining | PubMed |
| BPGM as an intrinsic brake to constrain metastasis through phospho-epigenetic-mediated carnitine biosynthesis suppression. | Neoplasia | 2026 | 41875824 | PubTator, text mining | PubMed |
| The JMJD family histone demethylases: structure, mechanism of action, diseases and therapeutic targets. | Mol Biomed | 2026 | 41857315 | PubTator, text mining | PubMed |
| chromIDEAS reveals epigenetic dynamics via multi-dimensional clustering of chromatin states. | Nucleic Acids Res | 2026 | 41816913 | PubTator, text mining | PubMed |
| The histone demethylase KDM4A promotes esophageal cancer progression by epigenetically activating LRG1-mediated TGF-β signaling. | Apoptosis | 2026 | 41811529 | PubTator, text mining | PubMed |
| Ferroptosis and cuproptosis in head and neck squamous cell carcinoma: interconnected mechanisms and therapeutic implications. | Front Pharmacol | 2026 | 41769686 | PubTator, text mining | PubMed |
| Fetal and Neonatal Immune Response to Congenital Cytomegalovirus (cCMV) Infection: A Systematically Conducted Scoping Review. | Viruses | 2026 | 41754585 | PubTator, text mining | PubMed |
| Chromatin Remodeling in VSMC Phenotype Switching During Vascular Remodeling: From Mechanism to Therapeutic Potential. | Biomolecules | 2026 | 41750335 | PubTator, text mining | PubMed |
| KDM4A Erases the H3R17me2a Mark, Facilitating Chromosome Condensation. | Adv Sci (Weinh) | 2026 | 41747073 | PubTator, text mining | PubMed |
| Genetic loss of CHD1 regulates distinct histone post-translational modifications in the development of castration-resistant prostate cancer. | Neoplasia | 2026 | 41720070 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/9682/papers